Stockreport

Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia

Cyclacel Pharmaceuticals, Inc.  (CYCC) 
Last cyclacel pharmaceuticals, inc. earnings: 2/26 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.cyclacel.com/investor-relations
PDF BERKELEY HEIGHTS, N.J., April 17, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutic [Read more]